Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT Plus Defactinib and Avutometinib in Advanced Pancreatic Cancer
NCT07126158Phase 2Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Apr 2026
- Primary completion
- Apr 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of defactinib, avutometinib in pancreatic adenocarcinoma (PDAC), sponsored by Washington University School of Medicine. Started Apr 2026; status: recruiting.
02
Drugs
defactinibavutometinib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07126158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07126158.